You're describing a chemical compound with a rather complex name, but let's break it down:
**[4-[(2,4-dichlorophenoxy)methyl]phenyl]-(4-methyl-1-piperazinyl)methanone**
* **Structure:** This compound is a **ketone** with a long, branched structure. It contains a phenyl ring substituted with a (2,4-dichlorophenoxy)methyl group at the 4-position, and a 4-methyl-1-piperazinyl group attached to the carbonyl carbon.
* **Key Features:**
* **2,4-Dichlorophenoxy group:** This group is often found in herbicides, making this compound potentially interesting for research related to plant biology or agriculture.
* **Piperazinyl group:** This group is known to be pharmacologically active and is often found in drugs targeting the central nervous system.
**Why is it important for research?**
Due to its structure, this compound could be relevant to several research areas:
* **Herbicide Research:** The presence of the 2,4-dichlorophenoxy group suggests potential herbicidal activity. Researchers could investigate its effectiveness in controlling weeds or its impact on plant growth.
* **Pharmaceutical Research:** The piperazinyl group could be involved in interactions with neurotransmitter receptors, making it a potential lead compound for developing drugs targeting the central nervous system.
* **Synthesis & Chemistry:** This compound could be used as a building block for synthesizing other complex molecules with potentially interesting biological activities.
**Important Note:** I cannot provide information on the exact properties or applications of this specific compound without further research. To determine its true importance, you'd need to:
* **Consult scientific databases:** Search for this compound in databases like PubChem or ChemSpider to find available information on its properties and known uses.
* **Review research publications:** Look for studies mentioning this specific compound or related analogues.
* **Contact experts:** Connect with researchers specializing in herbicide development, pharmaceutical chemistry, or related fields to get more specific insights.
ID Source | ID |
---|---|
PubMed CID | 1315470 |
CHEMBL ID | 1589080 |
CHEBI ID | 107891 |
Synonym |
---|
OPREA1_198047 |
MLS000062402 |
1-{4-[(2,4-dichlorophenoxy)methyl]benzoyl}-4-methylpiperazine |
smr000073090 |
CHEBI:107891 |
MLS002541723 |
AKOS001682859 |
STK915167 |
{4-[(2,4-dichlorophenoxy)methyl]phenyl}(4-methylpiperazin-1-yl)methanone |
[4-[(2,4-dichlorophenoxy)methyl]phenyl]-(4-methylpiperazin-1-yl)methanone |
HMS2497N17 |
REGID_FOR_CID_1315470 |
CHEMBL1589080 |
[4-[(2,4-dichlorophenoxy)methyl]phenyl]-(4-methyl-1-piperazinyl)methanone |
Q27186233 |
Class | Description |
---|---|
benzamides | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 28.1838 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 11.9955 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
TDP1 protein | Homo sapiens (human) | Potency | 22.1427 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 22.3872 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
IDH1 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 2.8184 | 0.0018 | 15.6638 | 39.8107 | AID894 |
ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 12.5893 | 0.6561 | 9.4520 | 25.1189 | AID927 |
geminin | Homo sapiens (human) | Potency | 23.1093 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 12.5893 | 1.5849 | 13.0043 | 25.1189 | AID927 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |